Postmenopausal women with hormone receptor-positive breast cancer may be prescribed Arimidex as part of endocrine treatment. Arimidex contains anastrozole, an oral aromatase inhibitor that lowers oestrogen production.
Reducing oestrogen can slow the growth of cancer cells that depend on this hormone. Arimidex tablets contain anastrozole, a non-steroidal aromatase inhibitor used in hormone-sensitive breast cancer. Anastrozole belongs to the triazole and nitrile chemical classes, which describes structural features of the molecule rather than separate active ingredients.
Arimidex is administered orally. The amount per intake and the total treatment plan are set individually, based on the cancer diagnosis, menopausal status, other therapies, and tolerance.
Arimidex tablets contain anastrozole, a non-steroidal aromatase inhibitor used in hormone-sensitive breast cancer. Anastrozole belongs to the triazole and nitrile chemical classes, which describes structural features of the molecule rather than separate active ingredients.
Aromatase inhibitors act differently from chemotherapy. They do not directly destroy cancer cells. Instead, they reduce the hormonal signal that fuels many oestrogen receptor-positive tumours.
Aromatase is an enzyme that converts androgens, produced mainly by the adrenal glands after menopause, into oestrogen. Anastrozole blocks aromatase, reducing circulating oestradiol and other forms of oestrogen.
This mechanism is most useful after menopause, when the ovaries are no longer the main source of oestrogen. In premenopausal women, the ovaries can respond to lower oestrogen by increasing hormone production. Ovarian suppression may therefore be required when an aromatase inhibitor is selected for a premenopausal patient.
ER-positive breast cancers use oestrogen as a growth signal. Lowering oestrogen deprives these cells of part of that signal, which can reduce recurrence risk after primary treatment or help control metastatic disease. The European Medicines Agency describes aromatase inhibition as a central endocrine approach for postmenopausal hormone-sensitive breast cancer. [1]
Arimidex is used for breast neoplasms that are hormone receptor-positive, with treatment plans tailored to tumour stage, receptor status, menopause status, prior therapies, and recurrence risk. It may be used after surgery for primary breast cancer or in treatment plans for metastatic, also called secondary, breast cancer.
Common clinical settings include:
Arimidex is not designed for every breast cancer subtype. Its benefit depends on tumour biology, especially whether cancer cells express oestrogen receptors. A pathology report guides this decision.
A common mistake is stopping Arimidex after a few weeks of aching joints without reporting the problem. Dose timing, exercise planning, pain management, bone assessment, or a change in endocrine strategy may be considered by the treating team.
Another mistake is taking a double dose after forgetting a tablet. This does not restore the missed exposure and can increase adverse effects.
People also sometimes assume that hot flashes mean treatment is working, or that no hot flashes mean it is failing. Neither assumption is reliable. Treatment response is assessed through the oncology follow-up plan, imaging when needed, physical examinations, and tumour-specific monitoring.
Arimidex is generally intended for postmenopausal hormone-sensitive breast cancer. It is not suitable for oestrogen receptor-negative disease as an endocrine treatment, because those cancer cells are not driven by oestrogen receptors.
Extra care is needed with:
Health Canada’s product monograph for anastrozole describes bone effects, cardiovascular considerations, and interaction concerns that should be assessed within the cancer treatment plan. [4]
This medication is not for you if you are pregnant, could be pregnant without an oncology-directed ovarian-suppression plan, are breastfeeding, or have had a serious allergic reaction to anastrozole or a tablet ingredient.
Arimidex suppresses estradiol, the main biologically active oestrogen. This reduction is systemic, meaning it affects more than breast tissue. Joint symptoms, vaginal dryness, hot flashes, and bone-density changes are linked to lower oestrogen exposure.
Hormone therapy works over months and years rather than by producing a daily sensation. Some people feel hot flashes quickly, while others notice little change. Neither experience alone proves whether treatment is controlling the cancer.
Ovarian suppression is a separate intervention that may be combined with endocrine treatment for selected premenopausal patients. It reduces ovarian hormone production and changes the endocrine setting in which an aromatase inhibitor can work. The World Health Organization recognizes endocrine therapy as a core treatment category for hormone-responsive breast cancer. [2]
Most adverse effects of anastrozole reflect oestrogen deprivation. Hot flashes, joint stiffness or pain, fatigue, headache, nausea, dry skin, vaginal dryness, and mood changes can occur. Bone mineral density may fall during longer treatment, increasing the risk of osteoporosis and fractures.
Bone health deserves attention. Oncology teams may arrange baseline and follow-up bone-density testing, assess vitamin D status, and consider bone-protective treatment when fracture risk is elevated.
Blood clots, including deep vein thrombosis (DVT) and pulmonary embolism (PE), require urgent assessment when symptoms occur. Tamoxifen has a more established thromboembolic risk than anastrozole, yet a new painful swollen leg, unexplained shortness of breath, chest pain, coughing blood, or sudden faintness should never be dismissed during cancer treatment.
The ATAC trial found that anastrozole produced fewer thromboembolic events than tamoxifen, while fractures and joint symptoms were more frequent with anastrozole. [3]
Arimidex and tamoxifen are both hormone therapies, though they interrupt oestrogen signalling in different ways. Anastrozole lowers oestrogen production. Tamoxifen blocks oestrogen receptors in breast tissue while having oestrogen-like actions in some other tissues.
| Treatment approach | Main action | Clinical profile |
|---|---|---|
| Arimidex (anastrozole) | Inhibits aromatase and lowers oestrogen | Often used after menopause; joint symptoms and bone loss need attention |
| Tamoxifen | Selective oestrogen receptor modulator | Used before or after menopause; clotting and uterine effects require attention |
An aromatase inhibitor may be selected when postmenopausal status is clear and reducing circulating oestrogen is the priority. Tamoxifen may be selected when its receptor-blocking mechanism better fits the treatment plan. Some patients use both approaches sequentially rather than remaining on one treatment throughout.
The trade-off is practical. Arimidex usually has less clotting and uterine risk than tamoxifen, yet it can be harder on joints and bone density.
In clinical practice, oncologists look beyond hot flashes when assessing whether Arimidex is tolerable. A patient may report only mild discomfort while quietly reducing walking, avoiding stairs, or sleeping poorly because of joint pain. Those changes matter because reduced mobility can worsen fatigue, stiffness, and bone health.
Doctors also distinguish manageable adverse effects from symptoms that need investigation. New hip, back, or rib pain is not automatically assigned to anastrozole-related joint symptoms. Cancer history, fracture risk, and the pattern of pain guide assessment.
Arimidex offers a well-established hormonal strategy for suitable postmenopausal patients. Its limitation is that low oestrogen affects bone and musculoskeletal comfort, so treatment often includes active monitoring rather than simply waiting for symptoms to become severe.
Arimidex can generally be taken with or without food. Food does not need to be used to activate the medicine, so the best schedule is the one that supports daily adherence. If nausea occurs, taking the tablet after a light meal may feel more comfortable. The FDA prescribing information updated in 2011 states that food does not materially affect anastrozole absorption.
Joint pain and stiffness are well-known effects of aromatase inhibitor therapy. Lower oestrogen can affect joint comfort, tendons, muscle recovery, and pain perception. The ATAC research programme, reported by The Lancet Oncology in 2010, found more musculoskeletal symptoms and fractures with anastrozole than with tamoxifen. New focal bone pain or pain that persists at rest needs clinical assessment rather than being automatically attributed to treatment.
Anastrozole has a long elimination half-life, so its aromatase-suppressing effect is designed for once-daily administration rather than short, symptom-based use. The purpose is steady oestrogen suppression over time. Missing one tablet does not mean treatment has instantly stopped working, though repeated missed doses can reduce consistency. The EMA assessment report for anastrozole, published in 2002, describes prolonged systemic exposure after oral administration.
The duration is individualized and can extend for years in adjuvant endocrine treatment when the expected reduction in recurrence risk outweighs adverse effects. Long-term use is common in breast cancer care, with bone density, fractures, cardiovascular factors, and tolerability reviewed during follow-up. The National Comprehensive Cancer Network breast cancer guidance, updated in 2025, includes aromatase inhibitors among established adjuvant endocrine options. The appropriate endpoint depends on tumour features and prior endocrine therapy.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
I took Arimidex after my oncology team confirmed ovarian suppression was part of my treatment plan. The first month brought hot flashes and sore fingers in the morning, but the stiffness eased after I started walking before work. I kept a symptom note for appointments, which made the conversations much more useful.
I had been taking it for four months after surgery. The daily tablet itself was easy, but my knees and hips felt stiff after long drives. My bone-density assessment and vitamin D discussion helped me understand why my team kept asking about fractures and exercise.
I used Arimidex for several months and found the fatigue and sleep disruption frustrating. The hot flashes were worse at night, and I was tempted to stop on my own. After I reported it, my care team adjusted the wider symptom plan, though the joint discomfort did not disappear completely.
